Healthcare
Live Price
Offline$260.00
+1.75% today
Window Change
+3.97%
Window
Jun 23, 2025 → May 14, 2026
Coverage: 226 bars · Jun 23, 2025 → May 14, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Bio-Rad Laboratories, Inc. (BIO-B) is a Healthcare stock with a market cap of $7.03B. The stock last traded around $260.00 and up 4.0% across the available one-year price window (Jun 23, 2025 → May 14, 2026). Baseline metrics include revenue growth of +0.7%, EPS growth of +142.6%, a dividend yield of 0.0%. What stands out right now is revenue +0.7%, EPS +142.6%, free cash flow +40.7% with operating margin 9.2% and ROIC 2.0%. Valuation already assumes a fairly strong business story at P/E 41.1 and price/sales 2.7. Stock Foundry combines BIO-B price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
BIO-B
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
BIO-B Max Drawdown
-20.42%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for BIO-B and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$2.9B
+4.3% YoY
FY Net Income
$4.3B
+217.3% YoY
Free Cash Flow
$535.7M
+567.2% YoY
Revenue Growth
+0.7%
EPS Growth
+142.6%
Gross Margin
51.9%
Net Margin
6.5%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 2.6B | 2.6B | 2.7B | 2.8B | 2.9B |
| Gross Profit | 1.3B | 1.4B | 1.4B | 1.6B | 1.6B |
| Operating Income | 271M | 269M | 338M | 483M | 500M |
| EBITDA | 476M | -2.1B | -655M | -4.5B | 5.6B |
| Net Income | 760M | -1.8B | -637M | -3.6B | 4.3B |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 532M | 488M | 404M | 434M | 471M |
| Total Assets | 10.6B | 9.4B | 12.3B | 13.5B | 17.8B |
| Total Liabilities | 3.1B | 2.8B | 3.6B | 3.9B | 4.1B |
| Shareholder Equity | 7.5B | 6.6B | 8.7B | 9.6B | 13.7B |
| Total Debt | 1.5B | 1.4B | 1.4B | 1.4B | 223M |
| Net Debt | 999M | 887M | 1.0B | 954M | -247M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
669M
+244.3% YoY
Capital Expenditures
134M
-17.2% YoY
Free Cash Flow
536M
+567.2% YoY
Key ratios
Gross Margin
51.9%
Operating Margin
9.2%
Net Margin
6.5%
ROE
2.4%
Debt / Equity
0.20x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.